Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00092040
NCT00092040
Completed
Phase 3

A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis

Organon and Co0 sites936 target enrollmentMarch 18, 2003
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsOsteoporosis, Postmenopausal

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Osteoporosis, Postmenopausal
Sponsor
Organon and Co
Enrollment
936
Primary Endpoint
Mean percent change from baseline in hip trochanter bone mineral density (BMD)
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.

Registry
clinicaltrials.gov
Start Date
March 18, 2003
End Date
September 28, 2005
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Postmenopausal women with osteoporosis

Exclusion Criteria

  • •Any known allergy to the study drug

Outcomes

Primary Outcomes

Mean percent change from baseline in hip trochanter bone mineral density (BMD)

Secondary Outcomes

  • Mean percent change from baseline in PA lumbar spine, total hip, and femoral neck BMD

Similar Trials

Completed
Phase 2
Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive PatientsHypertension
NCT00939588Novartis Pharmaceuticals88
Completed
Phase 4
A Study Evaluating Duloxetine in Patients Hospitalized for Severe DepressionMajor Depressive Disorder
NCT00422162Eli Lilly and Company339
Completed
Phase 3
Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)Exercise Induced Asthma
NCT00127166Organon and Co154
Completed
Phase 4
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment WithdrawalHypertension
NCT00865020Novartis822
Unknown
Phase 3
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 YearsAsthma
NCT03387241Mundipharma (China) Pharmaceutical Co. Ltd330